[1] Fan JG, Kim SU, Wong VWS. New trends on obesity and NAFLD in Asia. J Hepatol, 2017, 4: 862-873.
[2] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epide-miology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 1: 73-84.
[3] Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol, 2015, 1, Supplement: S47-S64.
[4] Eccleston HB, Andringa KK, Betancourt AM, et al. Chronic exposure to a high-fat diet induces hepatic steatosis, impairs nitric oxide bioavailability, and modifies the mitochondrial proteome in mice. Antioxid Redox Signal, 2011, 2: 447-459.
[5] Sampey BP, Vanhoose AM, Winfield HM, et al. Cafeteria diet is a robust model of human metabolic syndrome with liver and adipose inflammation: comparison to high-fat diet. Obesity (Silver Spring), 2011, 6: 1109-1117.
[6] Kristiansen MNB, Veidal SS, Rigbolt KTG, et al. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World J Hepatol, 2016, 16: 673-684.
[7] Handa P, Stevenson VM, Maliken BD, et al. Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steato-hepatitis in genetically obese mice. Am J Physiol Gastrointest Liver Physiol, 2016, 2: G117-G127.
[8] Lau JKC, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol, 2017, 1:36-44.
[9] Takahashi Y, Soejima Y, Fukusato T. Animal models of nonal-coholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol, 2012, 19:2300-2308.
[10] Yamada T, Obata A, Kashiwagi Y, et al. Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice. Magn Reson Imaging, 2016, 6: 724-729.
[11] Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol, 2004, 1: 47-51.
[12] Herck MAV, Vonghia L, Francque SM. Animal Models of Nonalcoholic Fatty Liver Disease-A Starter's Guide. Nutrients, 2017, 10: 1072.
[13] Minicis SD, Agostinelli L, Rychlicki C, et al. HCC develop-ment is associated to peripheral insulin resistance in a mouse model of NASH. PLoS One, 2014, 5: e97136-e97136.
[14] Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell, 2014, 4:549-564.
[15] Asgharpour A, Cazanave SC, Pacana T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol, 2016, 3:579-588.
[16] Fujii M, Shibazaki Y, Wakamatsu K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol, 2013, 3:141-152.
[17] Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol, 2010, 12:1436-1441.
[18] Minicis SD, Day C, Svegliati-Baroni G. From NAFLD to NASH and HCC: Pathogenetic mechanisms and therapeutic insights. Curr Pharm Des, 2013, 29:5239-5249.
[19] Thompson KJ, Swan RZ, Walling TL, et al. Obesity, but not ethanol, promotes tumor incidence and progression in a mouse model of hepatocellular carcinoma in vivo. Surg Endosc, 2013, 8: 2782-2791.
[20] Alkofer B, Lepennec V, Chiche L. Hepatocellular cancer in the non-cirrhotic liver. J Visc Surg, 2011, 1:3-11. |
